Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation

Inclusion Criteria: * Diagnosis of hematologic malignancies, indicated for allogeneic stem cell transplantation: * acute myeloid leukemia (AML), in CR1, ≥ CR2, primary refractory, relapse * chronic myeloid leukemia (CML), in chronic phase, in acceleration or blast crisis * myelodysplastic syndrome (MDS), RA/RARS (transfusion dependent), RAEB, RAEB-t and CMML * Lymphoma: * plasmocytoma * immunocytoma (M. Waldenström) * chronic-lymphatic leukemia (CLL) * additional low and high grade Non-Hodgkin Lymphoma * Hodgkins disease * HLA-matched (HLA-A, -B, -DRB1) related or unrelated donor available * Signed informed consent Exclusion Criteria: * CNS involvement by underlying disease * Pulmonary disease with VC \< 55%, DLCO \< 40% * Cardiac ejection fraction \< 30%, uncontrollable arrhythmia * Creatinin \> 1,5 mg/dl or Creatinin-Clearance \< 30 ml/min * Bilirubin \> 2 mg/dl * Active Hepatitis B or C * HIV serologic positive * Pregnancy and lactation * Pre-menstrual women without medical safe contraception * Participation on another clinical trial in between 30 days before start or during the study only if the clinical trial interferes with the outcome measures. * Known allergy to study medication or ingredients of the formulation * Drug- or alcohol abuse * Non-compliance